Mindful Eating Without medication controlling hunger, we guide patients to recognize true hunger signals and avoid binge cycles
Liraglutide and tirzepatide are effective for weight loss but have a poorer safety profile and higher discontinuation rates due to adverse events
These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
Regression analysis of restricted mean survival time based on pseudo-observations
The reality is that obesity and weight gain are not just matters of willpowerthey are complex medical conditions influenced by genetics, hormones, and metabolic adaptation
That balancing act, rather than raw receptor count, is what researchers are typically probing when they select Retatrutide over a single- or dual-agonist comparator
